Vascular Biogenics (NASDAQ:VBLT) Cut to Neutral at HC Wainwright

Vascular Biogenics (NASDAQ:VBLTGet Rating) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat Ratings reports.

Several other equities research analysts also recently weighed in on VBLT. Oppenheimer downgraded Vascular Biogenics from an “outperform” rating to a “market perform” rating in a research report on Wednesday. StockNews.com started coverage on Vascular Biogenics in a research report on Monday. They set a “sell” rating on the stock. Jonestrading restated a “buy” rating and set a $5.00 target price on shares of Vascular Biogenics in a research report on Friday, May 20th. Finally, Chardan Capital started coverage on Vascular Biogenics in a research report on Thursday, April 28th. They set a “buy” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.88.

Vascular Biogenics Stock Performance

Shares of VBLT opened at $0.38 on Wednesday. The business’s 50-day moving average is $1.60 and its two-hundred day moving average is $1.53. The company has a market capitalization of $26.07 million, a P/E ratio of -0.82 and a beta of 1.09. Vascular Biogenics has a fifty-two week low of $0.37 and a fifty-two week high of $2.54.

Vascular Biogenics (NASDAQ:VBLTGet Rating) last announced its quarterly earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.20 million. Vascular Biogenics had a negative return on equity of 69.21% and a negative net margin of 4,894.40%. During the same period in the prior year, the business posted ($0.12) earnings per share. Analysts forecast that Vascular Biogenics will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Vascular Biogenics

Institutional investors have recently bought and sold shares of the company. DLD Asset Management LP acquired a new stake in Vascular Biogenics in the 4th quarter worth about $837,000. Lion Point Capital LP acquired a new stake in Vascular Biogenics in the 4th quarter worth about $5,108,000. Advisor Group Holdings Inc. boosted its holdings in Vascular Biogenics by 49.2% in the 1st quarter. Advisor Group Holdings Inc. now owns 36,797 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 12,133 shares during the last quarter. Envestnet Asset Management Inc. acquired a new stake in Vascular Biogenics in the 1st quarter worth about $64,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Vascular Biogenics in the 4th quarter worth about $382,000. 26.15% of the stock is currently owned by institutional investors and hedge funds.

Vascular Biogenics Company Profile

(Get Rating)

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications.

See Also

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.